亚洲精品无码久久久久苍井空,办公室全肉高H湿play视频,亚洲AV无码成人片在线观苍井空,粉嫩AV一区二区三区在线,人妻91无码色偷偷色噜噜噜

中文
中文

以患者需求為核心,驅(qū)動細胞免疫治療創(chuàng)新,實現(xiàn)癌癥可控化并最終治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.
 

Breaking boundaries: Current progress of anticancer NK cell-based drug development
  • 0


Highlights

NK cells are safe in allogeneic applications and therefore are ideal off-the-shelf drugs.

NK cell-based therapeutics have shown satisfying safety profiles and promising efficiency in cancer treatment.

NK cells possess a reservoir of innate immune receptors targeting various types of cancer cells.

With proper engineering, NK cells can function as the universal anti-cancer drugs that are not restricted to HLA and cancer types.

 

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號

粵ICP備20056630號 Powered by vancheer
關(guān)于天科雅
研究與發(fā)展
產(chǎn)品及臨床
新聞與媒體

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號

粵ICP備20056630號 Powered by vancheer